| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
We investigated the efficacy of combined treatment with temsirolimus plus custirsen in a human RCC Caki-1 model. Although clusterin expression was increased by temsirolims, additional treatment of Caki-1 significantly inhibited clusterin upregulation. Combined treatment of temsirolimus and custirsen synergistically enhanced the sensitivity of Caki-1 to temsirolimus. Apoptotic changes were marked in Caki-1 following combined treatment with a sublethal dose of temsirolimus and custirsen, accompanying the significant downregulation of Mcl-1. In-vivo systemic administration of temsirolimus plus custirsen significantly inhibited the growth of Caki-1 tumors compared with that of temsirolimus plus control ODN.
Silencing of clusterin using custirsen resulted in the further enhancement of proapoptotic activity induced by temsirolimus in a human RCC model.
|
